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incidence
Ewing sarcoma (ES)/primitive neuroectodermal tumor (PNET)
of bone is the second most common primary malignant bone
cancer in children and adolescents, but is also seen in adults,
particularly the extraskeletal variety. The median age at
diagnosis is 15 years and there is a male predilection of 1.5/1.
ES is diagnosed in white Caucasians at an incidence of
0.3/100 000 per year, but is very uncommon in the African and
Asian population.
diagnosis
The first symptom of bone ES is usually pain—often
erroneously attributed to trauma. Plain radiographs in two
planes, complemented by computed tomography (CT) and/or
magnetic resonance imaging (MRI) are indicative of
a malignant tumor. Before biopsy patients with suggestive
findings should be sent to a reference centre with particular
experience in the disease. The definitive diagnosis is made by
biopsy, providing sufficient material for conventional histology,
immunohistochemistry and molecular biology (fresh, unfixed
material). ES is a small blue round-cell tumor, PAS- and CD99
(MIC2)-positive. All ES are high-grade tumors. While the
degree of neuronal differentiation used to be applied to
distinguish between classical ES and PNET, molecular biology
studies have now shown that all these tumors share a common
gene rearrangement involving the EWS gene on chromosome
22, so that this distinction is now obsolete. In most cases,
a reciprocal translocation t(11;22)(q24;q12) is found, but
t(21;22)(q22;q12) and others may also occur [t(7;22), t(17;22)
and t(2;22) translocations and inv(22)].
staging and risk assessment
Before biopsy, the description of the local extent of a bone
tumor requires radiographic and CT/MRI of the entire
involved bone, including adjacent joints and soft tissues. For
planning of local therapy, the precise involvement of bone,
bone marrow and soft tissues including the relationship to
critical structures like nerves or vessels, must be specified. A
chest CT scan is required to rule out lung or pleural metastases.
The assessment for bone and bone marrow metastases is to
include 99mTc bone scintigraphy, to detect osseous metastases,
and light microscopical examination of bone marrow aspirates
and biopsies taken at sites distant from the primary tumor.
Positron emission tomography (PET) scanning for bone
metastases and PCR techniques to investigate for bone marrow
metastases are sensitive methods currently under evaluation.
Additional appropriate imaging studies and biopsies should be
taken from suspicious sites, as the exact staging of the disease
has an impact on treatment and outcome [III, B].
About 20% of patients have ES of the pelvic bones, while
50% show extremity tumors. ES may involve any bone and (less
commonly in non-adult patients) soft tissues. Between 20%
and 25% of the patients are diagnosed with metastatic disease
(10% lung, 10% bones/bone marrow, 5% combinations or
others).
With surgery or radiotherapy alone, 5-year survival is <10%.
With treatment in current multimodality trials including
chemotherapy, survival is 60–70% in localized and 20–40%
in metastatic disease. Bone metastases confer a poorer outcome
than lung/pleura metastases (<20% compared with 20–40% 5-
year survival) [IIa, B]. Other known prognostic factors are
tumor size or volume, serum lactate dehydrogenase (LDH)
levels, axial localization or older age (>15 years). Under
treatment, poor histological response to preoperative
chemotherapy, and incomplete or no surgery for local therapy
are further adverse prognostic factors [IIa, B].
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treatment plan
As ES is a rare cancer, and its management is complex, the
accepted standard is treatment in reference centres or within
reference networks.
localized disease
Multimodal approaches within clinical trials, employing
combination chemotherapy and surgery and/or radiotherapy,
have raised 5-year survival rates from <10% to >60%. All
current trials employ three to six cycles of initial chemotherapy
after biopsy, followed by local therapy and another six to ten
cycles of chemotherapy usually applied at 3-week intervals.
Treatment duration is thus 8–12 months. Agents considered
most active include doxorubicin, cyclophosphamide,
ifosfamide, vincristine, dactinomycin and etoposide. Virtually
all active protocols are based on four- to six-drug combinations
of these substances. Protocols that have proved to be most
effective include at least one alkylating agent (ifosfamide or
cyclophosphamide) and doxorubicin [Ib, A].
Despite lively debate, complete surgery, where feasible, is
regarded as the best modality of local control. Radiotherapy
should be applied if complete surgery is impossible, and should
be discussed where histological response in the surgical
specimen was poor (i.e. >10% viable tumor cells) [IV, C]. In
one large series it was found that incomplete surgery followed
by radiotherapy was not superior to radiotherapy alone.
Radiotherapy is applied at doses of 40–45 Gy for microscopic
residues and 50–60 Gy for macroscopic disease [III, B].
Treatment of patients with extraskeletal ES follows the same
principles as for bone ES. Criteria for pathologic tumor
response assessment are less established. Radiation therapy is
used more extensively after surgery.
Treatment of adult patients follows the same principles.
However, tolerability of therapies in adults needs to be taken
into account when transferring treatment protocols conceived
for children and patients of age £30–40 years.
metastatic and recurrent disease
Outside specific clinical trials, patients with metastatic disease
ought to receive similar therapy to that given for localized
disease, with appropriate local treatment of metastases,
commonly applied as radiotherapy. Several non-randomized
trials have assessed the value of more intensive, time-
compressed or high-dose chemotherapy approaches, followed
by autologous stem cell rescue, but evidence of benefit, e.g.
resulting from randomized trials, is lacking [III, B]. In patients
with lung metastases, the resection of residual metastases after
chemotherapy, and possibly whole lung irradiation, may confer
a survival advantage [III, B]. Patients with bone or bone
marrow metastases and patients with recurrent disease still fare
poorly, with 5-year survival rates of £20%.
The only prognostic factor identified in relapse seems to be
time to relapse: patients relapsing later than 2 years from initial
diagnosis have a better outcome [III, B]. Doxorubicin therapy
is usually no longer feasible due to previously achieved
cumulative doses. Chemotherapy regimens in relapse situations
are not standardized and are commonly based on alkylating
agents (cyclophosphamide, ifosfamide) in combination with
topoisomerase inhibitors (etoposide, topotecan) or irinotecan
with temozolomide [III, B].
follow-up
Most relapses occur in the first 3 years of follow-up; late
relapses have rarely been observed even after 15 years or longer.
Besides the detection of relapse, long-term sequelae of
treatment are the main concern in long-term follow-up.
Impaired renal function may be observed early in follow-up,
but cardiac or pulmonary damage may become apparent later.
Secondary cancers may arise in irradiated sites. Secondary
leukemia, particularly acute myeloid leukemia may rarely be
observed independent of previous irradiation as early as 2–5
years after treatment [III, B]. Follow-up intervals should be 2–3
months during the first 3 years, 6 months until 5 years and at
least once yearly thereafter.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are
given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts and
the ESMO faculty.
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